The NMIBC Treatment Landscape: Emerging Evidence and Real-World Impact

home / peer-exchange / the-nmibc-treatment-landscape-emerging-evidence-and-real-world-impact

Experts take a deep dive into the latest advancement, exploring groundbreaking clinical trial data, real-world evidence of newly approved therapies, and ongoing research shaping the future of NMIBC, as well as addressing the practical challenges of bringing these innovations into practice.

Assessing Risk in NMIBC: A Foundation for Therapy

EP. 1: Assessing Risk in NMIBC: A Foundation for Therapy

Mark D. Tyson, II, MD, MPH;Bogdana Schmidt, MD, MPH;Sam S. Chang, MD, MBA;Aaron Berger, MD
May 8th 2025

Panelists discuss how precise risk stratification in non–muscle-invasive bladder cancer enables physicians to tailor treatment and surveillance strategies based on individual patient risk profiles.

From Papillary to CIS: Tailoring NMIBC Treatment

EP. 2: From Papillary to CIS: Tailoring NMIBC Treatment

Mark D. Tyson, II, MD, MPH;Bogdana Schmidt, MD, MPH;Sam S. Chang, MD, MBA;Aaron Berger, MD
May 8th 2025

Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer.

Defining and Managing BCG-Unresponsive NMIBC

EP. 3: Defining and Managing BCG-Unresponsive NMIBC

Mark D. Tyson, II, MD, MPH;Bogdana Schmidt, MD, MPH;Sam S. Chang, MD, MBA;Aaron Berger, MD
May 15th 2025

Panelists discuss how timely identification of BCG-unresponsive NMIBC through defined response criteria enables dynamic risk stratification and guides critical decisions about escalating care to alternative treatments.

NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up

EP. 4: NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up

Mark D. Tyson, II, MD, MPH;Bogdana Schmidt, MD, MPH;Sam S. Chang, MD, MBA;Aaron Berger, MD
May 15th 2025

Panelists discuss how maintenance BCG therapy and vigilant surveillance are essential for sustaining disease control in NMIBC patients, with treatment schedules and monitoring tailored to individual risk and tolerance.

© 2025 MJH Life Sciences

All rights reserved.